$5.79
0.00%
Nasdaq, Fri, Nov 13 2026.
ISIN
US14888D2080
Symbol
CSCI

Catalyst Biosciences, Inc. Stock News

Neutral
●
GlobeNewsWire
●
4 days ago
Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy data, including antitumor response for first-line non-small cell lung cancer (NSCLC) cohort in Q1 2027
Neutral
●
GlobeNewsWire
●
13 days ago
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 11,775 shares ...
Neutral
●
GlobeNewsWire
●
about one month ago
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a first-line non-small cell lung cancer (NSCLC) cohort Enrolling patients in CR-001 plus standard of care chemotherapy combinations from ASCEND expansion cohorts in several solid tum...
Neutral
●
GlobeNewsWire
●
about one month ago
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 81,525 shares ...
Neutral
●
GlobeNewsWire
●
about one month ago
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026
Neutral
●
GlobeNewsWire
●
about 2 months ago
WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares...
Neutral
●
GlobeNewsWire
●
2 months ago
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 58,650 shares...
Neutral
●
Business Wire
●
2 months ago
BOYNTON BEACH, Fla.--(BUSINESS WIRE)-- #CSCI--CSCI secures 12 new residential projects totaling 2,926 units across Florida as the structural shell contractor continues to gain market share.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today